GlassScriptPhysician profile
Robert Charles Becker
NPI 1477181105
$2,512.81
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $724 · 2023: $1,422 · 2024: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.46 |
| Education | $154.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $586.22 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $430.53 | 2022-2024 | Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $413.07 | 2022-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $329.87 | 2022-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $260.73 | 2022-2023 | |
| Corium, LLC | $128.09 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $96.26 | 2023 | Quviviq |
| Lundbeck LLC | $68.98 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $59.06 | 2023 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $42.41 | 2022 | |
| Indivior INC. | $42.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.90 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.63 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.